DaVita Inside: Expansion of At-Home Dialysis & Sustained ESRD Patient Growth To Shape The Future in Kidney Care!

DaVita Inc.’s third-quarter 2025 performance reflected a continuation of its strategic focus on providing high-quality kidney care amidst a challenging healthcare landscape. The company reported an adjusted operating income of $517 million, and adjusted earnings per share of $2.51, aligning with internal estimates but falling short of market expectations. The U.S. treatment volume showed a year-over-year decline of 1.5%, attributed to mixed operational days and census trends affected by a severe flu season, Hurricane Helene, and a cyber incident. Key initiatives continue to revolve around the company’s research efforts through DaVita Clinical Research (DCR), which has been pivotal in advancing kidney care treatment and obtaining FDA approval for ESKD drugs. The research’s potential to improve outcomes by exploring new therapies, such as middle molecule clearance, highlights DaVita’s long-term commitment to innovation in kidney care. Despite these advances, the financial dynamics present a complex picture.